BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016

1 of 3
BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016

Summary

‘BioMarin Pharmaceutical Inc. - Product Pipeline Review - 2016’, provides an overview of the BioMarin Pharmaceutical Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by BioMarin Pharmaceutical Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of BioMarin Pharmaceutical Inc.
- The report provides overview of BioMarin Pharmaceutical Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses BioMarin Pharmaceutical Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features BioMarin Pharmaceutical Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate BioMarin Pharmaceutical Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for BioMarin Pharmaceutical Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding BioMarin Pharmaceutical Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 3
List of Tables

List of Figures

BioMarin Pharmaceutical Inc. Snapshot

BioMarin Pharmaceutical Inc. Overview

Key Information

Key Facts

BioMarin Pharmaceutical Inc. - Research and Development Overview

Key Therapeutic Areas

BioMarin Pharmaceutical Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

BioMarin Pharmaceutical Inc. - Pipeline Products Glance

BioMarin Pharmaceutical Inc. - Late Stage Pipeline Products

Filing rejected/Withdrawn Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

BioMarin Pharmaceutical Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

BioMarin Pharmaceutical Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

BioMarin Pharmaceutical Inc. - Drug Profiles

amifampridine phosphate

Product Description

Mechanism of Action

R&D Progress

pegvaliase

Product Description

Mechanism of Action

R&D Progress

reveglucosidase alfa

Product Description

Mechanism of Action

R&D Progress

cerliponase alfa

Product Description

Mechanism of Action

R&D Progress

vosoritide

Product Description

Mechanism of Action

R&D Progress

BMN-250

Product Description

Mechanism of Action

R&D Progress

BMN-270

Product Description

Mechanism of Action

R&D Progress

Antisense RNAi Oligonucleotides to Activate Dysferlin for Dysferlinopathies

Product Description

Mechanism of Action

R&D Progress

PRO-052

Product Description

Mechanism of Action

R&D Progress

PRO-055

Product Description

Mechanism of Action

R&D Progress

PRO-135

Product Description

Mechanism of Action

R&D Progress

PRO-289

Product Description

Mechanism of Action

R&D Progress

RG-3250

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Sanfilippo Syndrome

Product Description

Mechanism of Action

R&D Progress

BioMarin Pharmaceutical Inc. - Pipeline Analysis

BioMarin Pharmaceutical Inc. - Pipeline Products by Target

BioMarin Pharmaceutical Inc. - Pipeline Products by Route of Administration

BioMarin Pharmaceutical Inc. - Pipeline Products by Molecule Type

BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action

BioMarin Pharmaceutical Inc. - Recent Pipeline Updates

BioMarin Pharmaceutical Inc. - Dormant Projects

BioMarin Pharmaceutical Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

BMN-044

BMN-045

BMN-053

drisapersen

BioMarin Pharmaceutical Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

BioMarin Pharmaceutical Inc. - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

BioMarin Pharmaceutical Inc., Key Information

BioMarin Pharmaceutical Inc., Key Facts

BioMarin Pharmaceutical Inc. - Pipeline by Indication, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2016

BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2016

BioMarin Pharmaceutical Inc. - Out-Licensed Products in Pipeline, 2016

BioMarin Pharmaceutical Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

BioMarin Pharmaceutical Inc. - Filing rejected/Withdrawn, 2016

BioMarin Pharmaceutical Inc. - Phase III, 2016

BioMarin Pharmaceutical Inc. - Phase II, 2016

BioMarin Pharmaceutical Inc. - Phase I, 2016

BioMarin Pharmaceutical Inc. - Preclinical, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Target, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Route of Administration, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Molecule Type, 2016

BioMarin Pharmaceutical Inc. - Pipeline Products by Mechanism of Action, 2016

BioMarin Pharmaceutical Inc. - Recent Pipeline Updates, 2016

BioMarin Pharmaceutical Inc. - Dormant Developmental Projects,2016

BioMarin Pharmaceutical Inc. - Discontinued Pipeline Products, 2016

BioMarin Pharmaceutical Inc., Other Locations

BioMarin Pharmaceutical Inc., Subsidiaries

BioMarin Pharmaceutical Inc., Key Manufacturing Facilities

List of Figures

BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Indication, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Stage of Development, 2016

BioMarin Pharmaceutical Inc. - Monotherapy Products in Pipeline, 2016

BioMarin Pharmaceutical Inc. - Out-Licensed Products in Pipeline, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Top 10 Target, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Route of Administration, 2016

BioMarin Pharmaceutical Inc. - Pipeline by Molecule Type, 2016

BioMarin Pharmaceutical Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll